Article
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
2025-09-26
Abstract excerpt
<h4>ABSTRACT</h4> Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chimeric antigen receptor (CAR) T-cells against T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective anti-tumor responses while preventing CAR T-cell fratricid...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 926977e5-f4ba-58e1-9981-2fa70b12dd20
- DOI
- 10.1101/2025.09.24.677515
